IBB : ISHARES NASDAQ BIOTECH IDX FD (AMEX)
All Headlines
Semi-Annual Changes to the Nasdaq Biotechnology Index
NEW YORK, Nov 12, 2001 /PRNewswire via COMTEX/ -- Effective with the market open on Monday, November 19, 2001, the components of Nasdaq Biotechnology Index(R) (Nasdaq: NBI chart, msgs) will change.
The following issues will be added to the Nasdaq Biotechnology Index: Albany Molecular Research, Inc. (Nasdaq: AMRI chart, msgs); Corixa Corporation (Nasdaq: CRXA chart, msgs); Exelixis, Inc. (Nasdaq: EXEL chart, msgs); Genta Incorporated (Nasdaq: GNTA chart, msgs); Immunomedics, Inc. (Nasdaq: IMMU chart, msgs); Isis Pharmaceuticals, Inc. (Nasdaq: ISIP chart, msgs); and Invitrogen Corporation (Nasdaq: IVGN chart, msgs).
Albany Molecular Research, Inc., headquartered in Albany, New York, is a chemistry-based drug discovery and development company, focusing on applications for new small molecule prescription drugs. The company conducts R&D projects and collaborates with many leading pharmaceutical, biotechnology and genomics companies, and is developing new chemistry technology for potential prescription drug applications.
Corixa Corporation, headquartered in Seattle, Washington, is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a stand-alone basis.
Exelixis, Inc., headquartered in South San Francisco, California, is a genomics-based drug discovery company focused on product development through its expertise in comparative genomics and model system genetics. These technologies provide a rapid, efficient and cost effective way to move from DNA sequence data to knowledge about the function of genes and the proteins they encode. Based upon its expertise, Exelixis has built an aggressive high- throughput screening and chemistry facility to accelerate these targets through the drug discovery process to develop effective new therapies for the treatment of cancer and other diseases.
Genta Incorporated, headquartered in Berkeley Heights, New Jersey, is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. The research platform is anchored by oligonucleotide chemistry, particularly applications of antisense and decoy aptamer technology. Genta's pipeline also comprises a portfolio of small molecules, including gallium-containing compounds for treatment of diseases associated with accelerated bone loss, and Androgenics compounds for prostate cancer.
Immunomedics, Inc., headquartered in Morris Plains, New Jersey, is a biopharmaceutical company focused on the development, manufacture and commercialization of therapeutic and diagnostic imaging products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection.
Isis Pharmaceuticals, Inc., headquartered in Carlsbad, California, is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs based on antisense technology. Isis has 12 antisense products in development. Isis' GeneTrove(TM) division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services and access to an extensive gene function database. Ibis Therapeutics(TM) is a division focused on the discovery of small molecule drugs that bind to RNA.
Invitrogen Corporation, headquartered in Carlsbad, California, develops, manufactures and markets research tools in kit form and provides other research products and services to biotechnology and biopharmaceutical researchers and companies worldwide. The company manufactures and markets thousands of products and services that simplify and improve gene cloning, gene expression, and gene analysis techniques for corporate, academic and government entities.
In January 2001, the Nasdaq Biotechnology Index was modified in order to become a better benchmark for financial products and the media. The Index includes companies primarily engaged in using biomedical research for the discovery or development of novel treatments or cures for human disease. In addition, all securities in the Index are listed on the Nasdaq National Market and meet minimum requirements for price, market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. In August, Nasdaq adopted maintenance criteria for the Biotechnology Index that allows companies to remain in the Index under separate standards. Index securities not meeting the maintenance criteria are retained in the Index provided that such security met the maintenance criteria in the previous ranking. Securities not meeting the maintenance criteria for two consecutive rankings are removed. As a result of the adoption of the maintenance criteria, no companies are being removed from the Index during this ranking. For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit nasdaq.com .
The Nasdaq Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index(SM) Fund (Amex: IBB chart, msgs), which seeks investment results that correspond generally to the price and yield performance before fees and expenses of the Index.
The Nasdaq Stock Market lists over 4,100 companies and trades more shares per day than any other U.S. market. For more information about Nasdaq, visit the Nasdaq Web site at nasdaq.com or the Nasdaq Newsroom(SM) at nasdaqnews.com .
iShares are distributed by SEI Investments Distribution Co. Barclays Global Fund Advisors serves as an advisor to iShares and is a subsidiary of Barclays Global Investors, neither of which is affiliated with SEI. For a prospectus, call 1-800-iSHARES (1-800-474-2737).
iShares are not FDIC Insured.
Have No Bank Guarantee.
May Lose Value.
CONTACT: John L. Jacobs, +1-202-496-2552, or Lisa Chaney, +1-202-496-2563, both of The Nasdaq Stock Market. |
